Clinical Trials
53 trialsNCT07227415 2026-05-22
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT04388852 2026-05-20
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03502733 2026-05-13
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04317105 2026-05-13
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04840589 2026-05-13
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05933265 2026-05-04
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Phase 1/2 Active not recruiting
NCT05219435 2026-04-24
VEXILLUM
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT02668770 2026-04-07
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05533697 2026-04-03
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.
Phase 2/3 Recruiting
NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT02408861 2026-01-21
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
NCT02374242 2025-12-10
ABC
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05631899 2025-11-24
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT06784648 2025-11-19
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
BioInvent International AB
Phase 1/2 Active not recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04283890 2025-09-09
CHOPIN
Leiden University Medical Center
Phase 1/2 Active not recruiting
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02259231 2025-06-04
RTA 408 Capsules in Patients With Melanoma - REVEAL
Biogen
Phase 1/2 Completed
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT05188118 2024-11-06
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT04739618 2024-07-23
Metastatic Solid Cancer Clinical Trial
ImmunSYS, LLC
Phase 2 Active not recruiting
NCT02113657 2024-05-24
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT04713371 2024-05-09
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
Phase 2 Active not recruiting
NCT01738139 2024-03-21
Ipilimumab and Imatinib Mesylate in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03126331 2024-03-18
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04892043 2024-02-23
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1 Terminated
NCT01856023 2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4 Terminated
NCT05631886 2023-08-28
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
Phase 1 Recruiting
NCT04084951 2023-04-14
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1 Completed
NCT03453892 2023-02-16
ST-ICI
University of Erlangen-Nürnberg Medical School
Completed
NCT02115139 2022-11-08
GRAY-B
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT04361162 2022-09-08
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02977156 2022-07-25
ISI-JX
Centre Leon Berard
Phase 1 Completed
NCT03219775 2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2 Unknown
NCT02239900 2020-11-30
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02221739 2020-05-11
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
NYU Langone Health
Phase 1/2 Completed
NCT01363206 2020-03-19
GIPI
Northern California Melanoma Center
Phase 2 Completed
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT02210104 2017-07-21
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01950195 2016-11-15
SRS (Stereotactic Radiosurgery) Plus Ipilimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated